Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance

Clinical Cancer Research

Volumn 9, Issue 4, 2003, Pages 1248-1252

  Marcucci, Guido ^a,b   Perrotti, Danilo ^a   Caligiuri, Michael A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; IMATINIB; PROTEIN INHIBITOR; RECOMBINANT ALPHA INTERFERON;

BCR ABL GENE; CANCER INHIBITION; CANCER RESISTANCE; CHROMOSOME 22; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; DRUG MECHANISM; DRUG RESISTANCE; HUMAN; MOLECULAR BIOLOGY; ONCOGENE; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES;

EID: 0348112599     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Sawyers, C. L. Chronic myeloid leukemia. N. Engl. J. Med., 340: 1330-1340, 1999.
2. Vardiman, J. W., Harris, N. L., and Brunning, R. D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100: 2292-2302, 2002.
3. Interferon α versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J. Natl. Cancer Inst., 89: 1616-1620, 1997.
4. Horowitz, M. M., Rowlings, P. A., and Passweg, J. R. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant, 17(Suppl. 3): S5-S6, 1996.
5. Clift, R. A., Radich, J., Appelbaum, F. R., Martin, P., Flowers, M. E., Deeg, H. J., Storb, R., and Thomas, E. D. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. Blood, 94: 3960-3962, 1999.
6. van Rhee, F., Szydlo, R. M., Hermans, J., Devergie, A., Frassoni, F., Arcese, W., de Witte, T., Kolb, H. J., Niederwiser, D., Jacobsen, N., Gahrton, G., Bandini, G., Carreras, E., Bacigalupo, A., Michallet, M., Ruutu, T., Reiffers, J., Goldman, J. M., Apperley, J., and Gratwohl, A. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant, 20: 553-560, 1997.
7. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037, 2001.
8. Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., and Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 344: 1038-1042, 2001.
9. Van Etten, R. A. Studying the pathogenesis of BCR-ABL+ leukemia in mice. Oncogene, 21: 8643-8651, 2002.
10. Pane, F., Intrieri, M., Quintarelli, C., Izzo, B., Muccioli, G. C., and Salvatore, F. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene, 21: 8652-8667, 2002.
11. Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., and Kantarjian, H. M. The biology of chronic myeloid leukemia. N. Engl. J. Med., 341: 164-172, 1999.
12. Zou, X., and Calame, K. Signaling pathways activated by oncogenic forms of Abl tyrosine kinase. J. Biol. Chem., 274: 18141-18144, 1999.
13. Perrotti, D., and Calabretta, B. Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins. Oncogene, 21: 8577-8583, 2002.
14. Trotta, R., Vignudelli, T., Candini, C., Intine, R., Pecorari, L., Guerzoni, C., Santilli, G., Byrom, B., Goldoni, G., Ford, L., Caligiuri, M., Maraia, R., Perrotti, D., and Calabretta, B. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell, 3: 145-160, 2003.
15. Osarogiagbon, U. R., and McGlave, P. B. Chronic myelogenous leukemia. Curr. Opin. Hematol., 6: 241-246, 1999.
16. Gordon, M. Y. Biological consequences of the BCR/ABL fusion gene in humans and mice. J. Clin. Pathol., 52: 719-722, 1999.
17. Druker, B. J. Imatinib alone and in combination for chronic myeloid leukemia. Semin. Hematol., 40: 50-58, 2003.
18. Sawyers, C. L., Hochhaus, A., Feldman, E., Goldman, J. M., Miller, C. B., Ottmann, O. G., Schiffer, C. A., Talpaz, M., Guilhot, F., Deininger, M. W., Fischer, T., O'Brien, S. G., Stone, R. M., Gambacorti-Passerini, C. B., Russell, N. H., Reiffers, J. J., Shea, T. C., Chapuis, B., Coutre, S., Tura, S., Morra, E., Larson, R. A., Saven, A., Peschel, C., Gratwohl, A., Mandelli, F., Ben-Am, M., Gathmann, I., Capdeville, R., Paquette, R. L., and Druker, B. J. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood, 99: 3530-3539, 2002.
19. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M., Druker, B., Goldman, J., O'Brien, S. G., Russell, N., Fischer, T., Ottmann, O., Cony-Makhoul, P., Facon, T., Stone, R., Miller, C., Tallman, M., Brown, R., Schuster, M., Loughran, T., Gratwohl, A., Mandelli, F., Saglio, G., Lazzarino, M., Russo, D., Baccarani, M., and Morra, E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med., 346: 645-652, 2002.
20. Talpaz, M., Silver, R. T., Druker, B. J., Goldman, J. M., Gambacorti-Passerini, C., Guilhot, F., Schiffer, C. A., Fischer, T., Deininger, M. W., Lennard, A. L., Hochhaus, A., Ottmann, O. G., Gratwohl, A., Baccarani, M., Stone, R., Tura, S., Mahon, F. X., Fernandes-Reese, S., Gathmann, I., Capdeville, R., Kantarjian, H. M., and Sawyers, C. L. Imatimb induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 99: 1928-1937, 2002.
21. Druker, B. J., O'Brien, S. G., Cortes, J., and Radich, J. Chronic myelogenous leukemia. Hematology (Am. Soc. Hematol. Educ. Program), 111-135, 2002.
22. Gorre, M. E., Ellwood-Yen, K., Chiosis, G., Rosen, N., and Sawyers, C. L. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood, 100: 3041-3044, 2002.
23. Gambacorti-Passerini, C. B., Gunby, R. H., Piazza, R., Galietta, A., Rostagno, R., and Scapozza, L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol., 4: 75-85, 2003.
24. Elmaagacli, A. H., Beelen, D. W., Opalka, B., Seeber, S., and Schaefer, U. W. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage. Ann. Hematol., 79: 424-431, 2000.
25. Perrotti, D., Cesi, V., Trotta, R., Guerzoni, C., Santilli, G., Campbell, K., Iervolino, A., Condorelli, F., Gambacorti-Passerini, C., Caligiuri, M. A., and Calabretta, B. BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2. Nat. Genet., 30: 48-58, 2002.
26. Honda, H., Ushijima, T., Wakazono, K., Oda, H., Tanaka, Y., Aizawa, S., Ishikawa, T., Yazaki, Y., and Hirai, H. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML. Blood, 95: 1144-1150, 2000.
27. Skorski, T., Nieborowska-Skorska, M., Wlodarski, P., Perrotti, D., Martinez, R., Wasik, M. A., and Calabretta, B. Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. Proc. Natl. Acad. Sci. USA, 93: 13137-13142, 1996.
28. Hochhaus, A., Kreil, S., Corbin, A. S., La Rosee, P., Muller, M. C., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N. C., Berger, U., Gschaidmeier, H., Druker, B. J., and Hehlmann, R. Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy. Leukemia (Baltimore), 16: 2190-2196, 2002.
29. O'Dwyer, M. E. Chronic myelogenous leukemia. Curr. Opin. Oncol., 15: 10-15, 2003.
30. Mohamed, A. N., Pemberton, P., Zonder, J., and Schiffer, C. A. The effect of imatinib mesylate on patients with philadelphia chromosome positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 00-00, 2003.
31. Schoch, C., Haferlach, T., Kern, W., Schnittger, S., Berger, U., Hehlmann, R., Hiddemann, W., and Hochhaus, A. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia (Baltimore), 17: 461-463, 2003.
32. Cortes, J. E., Talpaz, M., Giles, F., O'Brien, S., Rios, M. B., Shan, J., Garcia-Manero, G., Faderl, S., Thomas, D. A., Wierda, W., Ferrajoli, A., Jeha, S., and Kantarjian, H. M. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood, 2003.
33. Kantarjian, H. M., Talpaz, M., O'Brien, S., Giles, F., GarciaManero, G., Faderl, S., Thomas, D., Shan, J., Rios, M. B., and Cortes, J. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood, 101: 473-475, 2003.